About Us
Welcome to Maculaser, where innovation meets compassion in the realm of retinal care. Our groundbreaking retinal treatment leverages personalized heating to awaken the natural healing response of senescent cells. With a dedicated focus on disease prevention, we provide a non-damaging solution to address retinal disorders that impact millions globally.
Our Vision
Rooted in pioneering research in the top biomedical engineering laboratory at Aalto University, Finland, since 2013, Maculaser aims to revolutionize retinal healthcare. Targeting conditions like Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and Central Serous Chorioretinopathy (CSC), we strive to tackle the root causes of the diseases and make prevention a cornerstone of eye care. Our journey is advancing towards initiating our clinical trials.
Company Values
Focusing on patient safety, committed to science and evidence-based approaches, driven by outcome orientation, and inspired by engineering curiosity, our company values guide us to innovate and improve healthcare solutions. Each principle is integral to our dedication to advancing medical technology with integrity, precision, and a forward-thinking mindset.
Our Team
Jani Tirronen
CEO
Teemu Turunen
Chief Scientific Officer, PhD
Ossi Kaikkonen
Head of Product
Jaakko Nieminen
CTO, PhD
Aki Vartiainen
Clinical Trial Manager
Contact us
Follow how our solution develops
-
ZEISS Ventures and M2Care invest in Maculaser to advance temperature-controlled retinal laser therapy
Helsinki, 28 May 2026 ZEISS Ventures has joined Maculaser’s latest funding round, co-led together with M2Care. The investment marks the […]
-
Nature Communications publishes ERG-guided, temperature-controlled retinal laser study
Researchers at Aalto University, Karolinska Institutet / St. Erik Eye Hospital, and the University of Helsinki demonstrate that real-time electroretinography […]
-
Maculaser Joins €32M EU-Funded PhotonMed Initiative to Advance Retinal Care with Photonics
We are proud to announce that Maculaser is now part of PhotonMed, a €32 million European Union (Chips Joint Undertaking, […]